105 related articles for article (PubMed ID: 18366039)
1. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
Gao J; Liu YG; Liu R; Zingaro RA
ChemMedChem; 2008 Jun; 3(6):954-62. PubMed ID: 18366039
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
3. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
4. [Killing effect of 131I-Herceptin on breast cancer cell lines in vitro].
Lin J; Luo RC; Li AM; Zhang JY; Lü CW; Yan X
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):663-6. PubMed ID: 15958303
[TBL] [Abstract][Full Text] [Related]
5. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes.
Dullin A; Dufrasne F; Gelbcke M; Gust R
ChemMedChem; 2006 Jun; 1(6):644-53. PubMed ID: 16892405
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
Coley HM; Sarju J; Wagner G
J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
10. Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
Dullin A; Dufrasne F; Gelbcke M; Gust R
Arch Pharm (Weinheim); 2004 Dec; 337(12):654-67. PubMed ID: 15597399
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effect of novel platinum(II) and palladium(II) complexes on hepatic tumor stem cells in vitro.
Miklášová N; Fischer-Fodor E; Lönnecke P; Tomuleasa CI; Virag P; Schrepler MP; Mikláš R; Dumitrescu LS; Hey-Hawkins E
Eur J Med Chem; 2012 Mar; 49():41-7. PubMed ID: 22305340
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
14. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
15. [188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro].
Li GP; Zhang YF; Wang YX
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1455-7. PubMed ID: 17062351
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells.
Huang R; Sun Y; Gao Q; Wang Q; Sun B
Anticancer Drugs; 2015 Oct; 26(9):957-63. PubMed ID: 26186063
[TBL] [Abstract][Full Text] [Related]
18. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
19. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
20. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]